SCHEMBL24252748

SCHEMBL24252748

COc1ncc(B(O)O)cc1-c1ccc2c(N)nnc(C)c2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.34
KDR P35968 1/20 0.34
PIK3CA P42336 4/20 0.33
FYN P06241 6/20 0.32
CHEK2 O96017 2/20 0.32
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32
DHFR P00374 1/20 0.32
PLG P00747 1/20 0.32
F12 P00748 1/20 0.32
F11 P03951 1/20 0.32
KLKB1 P03952 1/20 0.32
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32
PRSS3 P35030 1/20 0.32
MAP4K4 O95819 1/20 0.31
MAPT P10636 1/20 0.31
CASP1 P29466 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452425 1.00 PDGFRB (0.34) PDGFRBKDRPIK3CAFYNCHEK2
SCHEMBL26771130 0.92 PIK3CA (0.33) PIK3CAFYNCHEK2ALOX5APFEN1
SCHEMBL24252269 0.81 DHFR (0.40) FYNCHEK2DHFRPLGF12
SCHEMBL30451411 0.81 PDGFRB (0.36) PDGFRBKDRPLGF12F11
SCHEMBL24252492 0.81 PDGFRB (0.36) PDGFRBKDRPLGF12F11
SCHEMBL24252659 0.81 DHFR (0.31) FYNCHEK2DHFRPLGF12
SCHEMBL24252685 0.79 PDGFRB (0.32) PDGFRBKDRFYN
SCHEMBL24252263 0.78 MAP4K4 (0.37) PLGF12F11KLKB1PRSS1
Formic Acid SCHEMBL25242412 0.77 DHFR (0.37) FYNCHEK2DHFRPLGF12
Formic Acid SCHEMBL30451288 0.77 DHFR (0.37) FYNCHEK2DHFRPLGF12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDGFRB 1234/4885KDR 3397/4885PIK3CA 2052/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDGFRB 1234/4885KDR 3397/4885PIK3CA 2052/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PDGFRB 1234/4885KDR 3397/4885PIK3CA 2052/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH PDGFRB 734/4885KDR 2637/4885PIK3CA 4098/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 PDGFRB 336/4885KDR 2338/4885PIK3CA 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.